Brentuximab Vedotin: A New Age in the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma

Relapse of Hodgkin's lymphoma (HL) after autologous stem cell transplantation (ASCT): Prognostic factors in 462 patients registered in the database of the EBMT.

(2017) C. Martinez et al.   JOURNAL OF CLINICAL ONCOLOGY

Hodgkin lymphoma: 2011 update on diagnosis, risk-stratification, and management

(2011) Stephen M. Ansell   AMERICAN JOURNAL OF HEMATOLOGY

Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma)

(2011) Claire E. Dearden et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

(2011) M. A. Fanale et al.   CLINICAL CANCER RESEARCH

Brentuximab Vedotin (SGN-35)

(2011) J. Katz et al.   CLINICAL CANCER RESEARCH

CD30-targeted antibody therapy

(2011) Anas Younes   CURRENT OPINION IN ONCOLOGY

CD30: an important new target in hematologic malignancies

(2011) Yehuda E. Deutsch et al.   LEUKEMIA & LYMPHOMA

Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate

(2010) N. M. Okeley et al.   CLINICAL CANCER RESEARCH

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-CD30 Antibodies for Hodgkin Lymphoma

(2010) Kelley V. Foyil et al.   Current Hematologic Malignancy Reports

ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

(2008) K. J. Savage et al.   BLOOD